Seraxis Wins Maryland Stem Cell Research Fund Grant to Accelerate Development of Allogenetically Compatible Pancreatic Islet Replacement Therapy for Functional Cure of T1D
$400,000 award will support characterization and efficacy testing of preclinical SR-03 cell line as a part of IND development. Seraxis is taking meetings at the...
Seraxis’ Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes
GMP-compliant manufacturing puts SR-02 on track to be industry’s second clinical-stage stem cell derived pancreatic islet transplant program. The third-party auditor’s FDA six-system approach yielded...
Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA
Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and...